Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00038545

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Herceptin
Drug: Taxol
Drug: Fluorouracil
Drug: Cytoxan
Drug: Epirubicin

First Posted Date: 2002-05-31

Last Posted Date: 2012-07-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT00038402

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Estramustine
Drug: Taxol

First Posted Date: 2002-05-30

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00038168

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: cetuximab
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2002-05-01

Last Posted Date: 2010-04-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT00034541

Locations: 🇺🇸
ImClone Investigational Site, Indianapolis, Indiana, United States

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Neoplasm Metastasis
Lung Cancer

First Posted Date: 2002-04-26

Last Posted Date: 2007-12-24

Lead Sponsor: Amgen

Target Recruit Count: 194

Registration Number: NCT00034346

Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

Phase 2

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Baker Norton Pharmaceuticals

Registration Number: NCT00002189

Locations: 🇺🇸
Massachusetts Gen Hosp / AIDS Oncology Research, Boston, Massachusetts, United States

Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis

Phase 1

Completed

Conditions: Carcinoma
Peritoneal Neoplasm

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00001569

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Neoplasm

First Posted Date: 1999-11-04

Last Posted Date: 2018-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT00001426

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy